Claims for Patent: 9,844,510

Summary for Patent: 9,844,510

Title:	Ulipristal acetate tablets
Abstract:	The invention relates to a pharmaceutical tablet for oral administration comprising ulipristal acetate together with the following excipients: at least one diluent in an amount of 50 to 98.5 wt %, at least one binding agent in an amount of 0 to 10 wt %, at least one disintegrating agent in an amount of 0.5 to 10 wt %, and at least one lubricant in an amount of 0 to 10 wt %.
Inventor(s):	Gainer; Erin (Paris, FR), Guillard; Helene (Paris, FR), Gicquel; Denis (Orgeval, FR), Henrion; Marianne (Paris, FR), Gnakamene; Celine (Paris, FR)
Assignee:	Laboratoire HRA-Pharma (Paris, FR)
Application Number:	15/185,508
Patent Claims:	1. An oral pharmaceutical tablet comprising from 1 to 18 wt % ulipristal acetate, wherein ulipristal acetate is present in an amount ranging from 1 mg to 50 mg, 50 to 98.5 wt % of a diluent, 0.5 to 10 wt % of croscarmellose sodium, and 0.5 to 5 wt % of magnesium stearate, 0 to 10 wt % of a binding agent, wherein at least 80% of ulipristal acetate present in the tablet is dissolved within about 20 minutes when said tablet is subjected to an in vitro dissolution assay in a paddle apparatus at 37.degree. C..+-.0.5.degree. C., and in HCl 0.1N as dissolution medium. 2. The tablet of claim 1, wherein at least 90% of ulipristal acetate present in the tablet is dissolved within about 20 minutes when the said tablet is subjected to an in vitro dissolution assay in a paddle apparatus at 37.degree. C..+-.0.5.degree. C., a rotation speed of 50 rpm, and in HCl 0.1N as dissolution medium. 3. The tablet of claim 1, which comprises a binding agent. 4. The tablet of claim 3, wherein the binding agent is a synthetic or natural polymer. 5. The tablet of claim 4 wherein the binding agent is povidone and/or hydroxypropyl methyl cellulose. 6. The tablet of claim 1, wherein the diluent is selected from the group consisting of monosaccharides, disaccharides, calcium phosphate, sodium phosphate, calcium carbonate, sodium carbonate, cellulose, microcrystalline cellulose, combinations and hydrates thereof. 7. The tablet of claim 6, wherein the diluent is selected from the group consisting of mannitol, lactose, microcrystalline cellulose, hydrates thereof and combinations thereof. 8. The tablet of claim 1, which comprises: from 3% to 18% by weight of ulipristal acetate. 9. The diluent of claim 1, wherein the diluent is in an amount of 65 to 92 wt %. 10. The tablet of claim 1, wherein croscarmellose sodium is in an amount of 1.5 to 8.5 wt %. 11. The tablet of claim 1, comprising from 5 to 30 mg of ulipristal acetate. 12. The tablet of claim 1, which is uncoated. 13. The tablet of claim 1, wherein ulipristal acetate is micronized. 14. A method of manufacturing an oral ulipristal acetate tablet of claim 1, the method comprising the step of mixing the ingredients and ulipristal acetate and forming a tablet, by wet granulation or by direct compression. 15. The tablet of claim 1 which is coated. 16. The tablet of claim 1 which comprises from 65% to 92% by weight of a diluent, the diluent being a mixture of mannitol and cellulose microcrystalline, and from 0.5% to 4% by weight of magnesium stearate, and wherein ulipristal acetate is present at a dosage ranging from 5 mg to 30 mg. 17. The tablet of claim 1 which is devoid of any binding agent.